Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02257320Not ApplicableCompleted

TMJ NextGeneration(TM) Feasibility Study

Role: lead

NCT02446288Not ApplicableUnknown

TMJ NextGen Pilot Study to Treat Subjects With Bruxism

Role: collaborator

NCT02269553Not ApplicableWithdrawn

TMJ-1001 Bruxism Run-In/Pivotal Trial

Role: lead

All 3 trials loaded